Intellia Therapeutics (LSE:0JBU) - Cotización, noticias y análisis

Resumen de acción 0JBU

Intellia Therapeutics, Inc. es una empresa de edición genómica centrada en el desarrollo de terapias curativas.

0JBU fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Recompensas

Se prevé un crecimiento anual de los ingresos de 56.8%

Análisis de riesgos

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Los accionistas han sido diluidos en el último año

Volatilidad del precio de la acción en los últimos 3 meses

Competidores de Intellia Therapeutics, Inc.

Genus

LSE:GNS

UK£1.1b

PureTech Health

LSE:PRTC

UK£589.1m

NIOX Group

AIM:NIOX

UK£282.4m

Bioventix

AIM:BVXP

UK£232.3m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Intellia Therapeutics
Historical stock prices
Current Share Price	US$20.76
52 Week High	US$46.91
52 Week Low	US$19.37
Beta	1.8
1 Month Change	-26.22%
3 Month Change	-16.17%
1 Year Change	-45.50%
3 Year Change	-72.08%
5 Year Change	23.89%
Change since IPO	-15.97%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	0JBU	GB Biotechs	Mercado GB
7D	-5.7%	2.1%	1.4%
1Y	-45.5%	-27.7%	1.1%

Rentabilidad vs. Industria: 0JBU obtuvo unos resultados inferiores a los del sector UK Biotechs , que el año pasado arrojó un rendimiento del -27.7%.

Rentabilidad vs. Mercado: 0JBU obtuvo unos resultados inferiores a los del mercado UK, que fue del 0.6% el año pasado.

Volatilidad de los precios

Is 0JBU's price volatile compared to industry and market?
0JBU volatility
0JBU Average Weekly Movement	9.4%
Biotechs Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	11.3%
10% least volatile stocks in GB Market	2.7%

Precio estable de las acciones: El precio de las acciones de 0JBU ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de 0JBU(9%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de UK.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
2014	526	John Leonard	www.intelliatx.com

Intellia Therapeutics, Inc. es una empresa de edición genómica centrada en el desarrollo de terapias curativas. Los programas in vivo de la empresa incluyen NTLA-2001, que se encuentra en ensayo clínico de fase 1 para el tratamiento de la amiloidosis por transtiretina; NTLA-2002 para el tratamiento del angioedema hereditario; y NTLA-3001 para la enfermedad pulmonar asociada a la deficiencia de alfa-1 antitripsina. También se centra en programas que comprenden la hemofilia A y la hemofilia B; y la investigación de programas propios centrados en el desarrollo de terapias celulares de ingeniería para tratar diversos tipos de cáncer y enfermedades autoinmunes.

Resumen de fundamentos de Intellia Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Intellia Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de 0JBU
Capitalización bursátil	US$2.00b
Beneficios(TTM)	-US$481.19m
Ingresos (TTM)	US$36.28m

55.2x

Ratio precio-ventas (PS)

-4.2x

Ratio precio-beneficio (PE)

¿Está 0JBU sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de 0JBU
Ingresos	US$36.28m
Coste de los ingresos	US$435.07m
Beneficio bruto	-US$398.79m
Otros gastos	US$82.40m
Beneficios	-US$481.19m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-4.99
Margen bruto	-1,099.36%
Margen de beneficio neto	-1,326.51%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado 0JBU a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción 0JBU

Recompensas

Análisis de riesgos

Competidores de Intellia Therapeutics, Inc.

LSE:GNS

UK£1.1b

LSE:PRTC

UK£589.1m

AIM:NIOX

UK£282.4m

AIM:BVXP

UK£232.3m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

Intellia Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $375.727167 million.

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$5.42 loss per share (vs US$6.16 loss in FY 2022)

New major risk - Revenue and earnings growth

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Recent updates

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

Intellia Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $375.727167 million.

New minor risk - Shareholder dilution

Full year 2023 earnings released: US$5.42 loss per share (vs US$6.16 loss in FY 2022)

New major risk - Revenue and earnings growth

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics, Inc. to Report Q4, 2023 Results on Feb 22, 2024

Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

President recently sold US$566k worth of stock

Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees

Third quarter 2023 earnings released: US$1.38 loss per share (vs US$1.49 loss in 3Q 2022)

New minor risk - Share price stability

Intellia Therapeutics, Inc. Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 At the 4th International ATTR Amyloidosis Meeting

Insufficient new directors

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Second quarter 2023 earnings released: US$1.40 loss per share (vs US$1.33 loss in 2Q 2022)

Intellia Therapeutics, Inc. Appoints Eliana Clark, Phd, Executive Vice President and Chief Technical Officer

Intellia Therapeutics, Inc. Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Announces Resignation of Jean-François Formela as Board Member

First quarter 2023 earnings released: US$1.18 loss per share (vs US$1.97 loss in 1Q 2022)

Full year 2022 earnings released: US$6.16 loss per share (vs US$3.78 loss in FY 2021)

President recently sold US$248k worth of stock

Intellia Therapeutics Presents New Interim Data from First-In-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001

Third quarter 2022 earnings released: US$1.49 loss per share (vs US$0.97 loss in 3Q 2021)

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema at the 2022 ACAAI Annual Scientific Meeting

Intellia Therapeutics Announces Positive Interim Clinical Data for its Second Systemically Delivered Investigational CRISPR Candidate, NTLA-2002 for the Treatment of Hereditary Angioedema (HAE)

Intellia Therapeutics, Inc. Receives U.S. FDA Orphan Drug Designation for NTLA-2002, an Investigational CRISPR Therapy for the Treatment of Hereditary Angioedema

Intellia Therapeutics, Inc. to Present Interim Clinical Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema At the 2022 Bradykinin Symposium

Second quarter 2022 earnings released: US$1.33 loss per share (vs US$1.01 loss in 2Q 2021)

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announces Additional Positive Interim Data from an Ongoing Phase 1 Study of Their Lead Investigational in Vivo Genome Editing Candidate, NTLA-2001

Intellia Therapeutics to Present Updated Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the International Liver Congress™ 2022

First quarter 2022 earnings released: US$1.97 loss per share (vs US$0.69 loss in 1Q 2021)

Intellia Therapeutics, Inc. Names Muna Bhanji to Its Board of Directors

Intellia Therapeutics, Inc., Annual General Meeting, Jun 14, 2022

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Clinical Trial of NTLA-5001 for Treatment of Acute Myeloid Leukemia

Intellia Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. Announce Updated Phase 1 Data Demonstrating a Single Dose of NTLA-2001, an Investigational CRISPR Therapy for Transthyretin (ATTR) Amyloidosis, Resulted in Rapid, Deep and Sustained Reduction in Disease-Causing Protein

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Intellia Therapeutics, Inc. (NasdaqGM : NTLA) acquired Rewrite Therapeutics, Inc. for $200 million.

Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of NTLA-2002 for the Treatment of Hereditary Angioedema

Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy

Third quarter 2021 earnings released: US$0.97 loss per share (vs US$0.47 loss in 3Q 2020)

Intellia Therapeutics, Inc. announces U.S. Food and Drug Administration accept the investigational new drug (IND) application for NTLA-5001

Second quarter 2021 earnings released: US$1.01 loss per share (vs US$0.61 loss in 2Q 2020)

Intellia Therapeutics, Inc.(NasdaqGM:NTLA) dropped from Russell 3000E Index

Intellia Therapeutics to Present Interim Clinical Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2021 Peripheral Nerve Society Annual Meeting

First quarter 2021 earnings released: US$0.69 loss per share (vs US$0.63 loss in 1Q 2020)

Intellia Therapeutics, Inc. Announces the Presentation of New Data from Its CRISPR/Cas9 Platform

Intellia Therapeutics Presents Preclinical Proof of Concept for CRISPR-based In Vivo Editing of Bone Marrow at Keystone eSymposium

Full year 2020 earnings released: US$2.40 loss per share (vs US$2.11 loss in FY 2019)

Revenue misses expectations

Intellia Therapeutics, Inc. Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Intellia Therapeutics, Inc.

55.2x

-4.2x

Beneficios e Ingresos